1) Nimotuzumab
尼妥珠单抗
1.
Primary study of nimotuzumab combined with radiotherapy and concomitant temozolomide chemotherapy treatment for high-grade glioma
尼妥珠单抗联合放疗加同期替莫唑胺治疗高分级胶质瘤的初步研究
2) Trastuzumab
曲妥珠单抗
1.
Advances in resistance mechanisms of trastuzumab HER2 monoclonal antibody;
HER2单抗曲妥珠单抗耐药机制研究进展
2.
Results of Two Open-label, Multicenter Phase Ⅱ Studies of Docetaxel, Platinum Salts, and Trastuzumab in HER-2 Positive Advanced Breast Cancer;
多西他赛、铂盐加曲妥珠单抗在HER-2阳性进展期乳腺癌中的两个开放、多中心的Ⅱ期研究结果
3.
Pharmacokinetics, Safety, and Efficacy of Trastuzumab Administered Every Three Weeks in Combination with Paclitaxel for the Treatment of HER-2 Positive Metastatic Breast Carcinoma;
曲妥珠单抗每三周方案联合紫杉醇治疗HER-2阳性转移性乳腺癌的药代动力学、安全性及有效性研究
3) Trastuzumab prognosis
曲妥珠单抗、预后
4) Tuvirumab
妥韦单抗
5) Cetuximab
西妥昔单抗
1.
Evaluation of Cetuximab in combination with radiotherapy or chemotherapy against advanced squamous cell carcinoma of the head and neck;
西妥昔单抗联合化疗或放疗治疗晚期头颈鳞癌的疗效评价(英文)
2.
Effects of Cetuximab Combined Erlotinib on Proliferation of Human Hepatocellular Carcinoma Cell Lines HepG2 and Bel-7402;
西妥昔单抗联合厄洛替尼对人肝癌细胞的体外抑制作用
3.
Clinical observation of combination chemotherapy for metastatic colorectal cancer with Cetuximab;
西妥昔单抗联合化疗治疗转移性结直肠癌的临床观察
6) Rituximab
利妥昔单抗
1.
Effectiveness and pharmacoeconomic evaluation of rituximab for treatment of non-Hodgkin s lymphoma;
利妥昔单抗对于非霍奇金淋巴瘤的治疗及其药物经济学
2.
Rituximab in Combination with CHOP Scheme for Non-Hodgkin s Lymphoma: Evaluation of Clinical Efficacy;
利妥昔单抗联合CHOP方案治疗NHL的临床疗效评价
3.
Expression of CD16ζ in NK Cells of B-cell Non-Hodgkin s Lymphoma Patients and In Vitro Killing Effect of Rituximab Combined Lymphokine-activated Killer Cells on B-NHL Cells;
B-NHL患者NK细胞中CD16ζ表达及利妥昔单抗与LAK细胞的联合抗瘤作用
补充资料：妥曲珠利
分子式：C18H14F3N3O4S
分子量：425.39
CAS号：暂无
性质：暂无
制备方法：暂无
用途：用于防治球虫病，广泛用于家禽和家畜球虫病的预防和治疗。独特杀虫方式，只需用药2d即可，可与任何药物混合使用，安全性高，显著降低死亡率。
分子量：425.39
CAS号：暂无
性质：暂无
制备方法：暂无
用途：用于防治球虫病，广泛用于家禽和家畜球虫病的预防和治疗。独特杀虫方式，只需用药2d即可，可与任何药物混合使用，安全性高，显著降低死亡率。
说明：补充资料仅用于学习参考，请勿用于其它任何用途。
参考词条